Melanie Ward, MD
Neurology · Morgantown, WVNPI 1740571504
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,521 of the $9,013 with a category attached, or 72.3%. 16 manufacturers reported payments, led by EMD Serono, Inc. at 24.8% of the total. Reporting peaked in 2020 at $3,766 and has fallen 92.5% since, to $282 in 2025.
Across 53 payments — averaging $170.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$2K
- Novartis$2K
- Genentech, Inc.$2K
- Bristol Myers Squibb$1K
- Biogen$427
- AstraZeneca$254
- plus $1K from 10 others
Across 48 payments — averaging $28,536 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.1M
- Genentech, Inc.$226K
- Sanofi$69K
What the payments were for
- Consulting fees$6,52172%
- Food & beverage$2,05523%
- Education$4385%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 6 | $2,233 |
| Novartis | 7 | $1,962 |
| Genentech, Inc. | 4 | $1,635 |
| Bristol Myers Squibb | 1 | $1,440 |
| Biogen | 9 | $427 |
| AstraZeneca | 5 | $254 |
| Amgen(2 entities) | 3 | $240 |
| TG Therapeutics, Inc. | 2 | $203 |
| Sanofi | 3 | $194 |
| Genentech USA, Inc. | 1 | $108 |
| AbbVie | 5 | $104 |
| Johnson & Johnson | 1 | $95 |
| UCB, Inc. | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 1 | $41 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,013 in reported general payments places this provider in the 75th percentile of 93 neurology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 83 | $770,482 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $104,846 |
| CopaxoneGlatiramer Acetate | 15 | $88,294 |
| Teriflunomide | 35 | $51,040 |
| Glatiramer Acetate | 15 | $35,115 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $16,625 |
| Dalfampridine ErDalfampridine | 34 | $10,779 |
| Dimethyl Fumarate | 15 | $3,222 |
| Gabapentin | 168 | $2,060 |
| Baclofen | 125 | $1,508 |
| Rivastigmine | 15 | $1,470 |
| Memantine Hcl | 72 | $1,178 |
| Donepezil Hcl | 138 | $1,162 |
| Levetiracetam | 33 | $1,082 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 41 | $1,020 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $18 | $88,29415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 93 neurology providers in West Virginia.
Other neurology in Morgantown
- Umer NajibMorgantown$246K
- Cheryl SmithMorgantown$68K
- Mouhannad AzzouzMorgantown$40K
- Maria Moreno EscobarMorgantown$23K
- Shumaila SultanMorgantown$13K
- Ann MurrayMorgantown$12K
- Violina MelnicMorgantown$12K
- Richa TripathiMorgantown$8K
- Phong VuMorgantown$5K
- Ruchi DhyaniMorgantown$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.